Machine learning (ML), a major branch of artificial intelligence, has not only demonstrated the potential to significantly improve numerous sectors of healthcare but has also made significant contributions to the field of solid organ transplantation. ML provides revolutionary opportunities in areas such as donor-recipient matching, post-transplant monitoring, and patient care by automatically analyzing large amounts of data, identifying patterns, and forecasting outcomes.

To conduct a comprehensive bibliometric analysis of publications on the use of ML in transplantation to understand current research trends and their implications.

On July 18, a thorough search strategy was used with the Web of Science database. ML and transplantation-related keywords were utilized. With the aid of the VOS viewer application, the identified articles were subjected to bibliometric variable analysis in order to determine publication counts, citation counts, contributing countries, and institutions, among other factors.

Of the 529 articles that were first identified, 427 were deemed relevant for bibliometric analysis. A surge in publications was observed over the last four years, especially after 2018, signifying growing interest in this area. With 209 publications, the United States emerged as the top contributor. Notably, the "Journal of Heart and Lung Transplantation" and the "American Journal of Transplantation" emerged as the leading journals, publishing the highest number of relevant articles. Frequent keyword searches revealed that patient survival, mortality, outcomes, allocation, and risk assessment were significant themes of focus.

The growing body of pertinent publications highlights ML's growing presence in the field of solid organ transplantation. This bibliometric analysis highlights the growing importance of ML in transplant research and highlights its exciting potential to change medical practices and enhance patient outcomes. Encouraging collaboration between significant contributors can potentially fast-track advancements in this interdisciplinary domain.

Liver cirrhosis affects millions of individuals worldwide and is one of the primary causes of mortality. Early mortality prediction for cirrhosis patients may increase the possibility for medical professionals to treat the illness successfully. This study assesses the ability of machine learning (ML) models to predict cirrhosis mortality. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to search for relevant literature across four different databases. We found 379 studies of which 10 were eligible for inclusion in the current study. We analyzed 10 retrospective studies that showed that ML models outperformed conventional scores in predicting the death rate from end-stage liver disease (ESLD). Interestingly, models that used more parameters, such as patient demographics and extensive laboratory testing, exhibited higher prediction accuracy. With an area under the receiver operating characteristic (AUROC) ranging from 0.71 to 0.96, ML models showed consistently significant gains over traditional prognostic ratings. This review emphasizes how ML models might improve ESLD patient death prediction. Because machine learning models are more accurate than conventional approaches, it is important to incorporate data-driven informatics technologies into clinical settings. Additional validation and openness are required to guarantee model dependability and interpretability before ML may be used in clinical practice. The goal of future research should be to create reliable, interpretable models that may be used successfully in a variety of clinical contexts, enhancing ESLD patient treatment and results.

Critically ill patients with liver cirrhosis generally have a poor prognosis due to complications such as multiple organ failure. This study aims to develop a machine learning-based prediction model to forecast short-term mortality in critically ill cirrhotic patients in the intensive care unit (ICU), thereby assisting clinical decision-making for intervention and treatment.

Machine learning models were developed using clinical data from critically ill cirrhotic patients in the MIMIC database, with multicenter validation performed using data from the eICU database and Qinghai University Affiliated Hospital(QUAH). Various machine learning models, including a Stacking ensemble model, were employed, with the SHAP method used to enhance model interpretability.

The Stacking ensemble model demonstrated superior predictive performance through internal and external validation, with AUC and AP values surpassing those of individual algorithms. The AUC values were 0.845 in the internal validation set, 0.819 in the eICU external validation, and 0.761 in the QUAH validation set. Additionally, the SHAP method highlighted key prognostic variables such as INR, bilirubin, and urine output. The model was ultimately deployed as a web-based calculator for bedside decision-making.

The machine learning model effectively predicts short-term mortality risk in critically ill cirrhotic patients in the ICU, showing strong predictive performance and generalizability. The model's robust interpretability and its deployment as a web-based calculator suggest its potential as a valuable tool for assessing the prognosis of cirrhotic patients.

Liver cirrhosis stands as a prominent contributor to mortality, impacting millions across the United States. Enabling health care providers to predict early mortality among patients with cirrhosis holds the potential to enhance treatment efficacy significantly. Our hypothesis centers on the correlation between mortality and laboratory test results along with relevant diagnoses in this patient cohort. Additionally, we posit that a deep learning model could surpass the predictive capabilities of the existing Model for End-Stage Liver Disease score. This research seeks to advance prognostic accuracy and refine approaches to address the critical challenges posed by cirrhosis-related mortality. This study evaluates the performance of an artificial neural network model for liver disease classification using various training dataset sizes. Through meticulous experimentation, three distinct training proportions were analyzed: 70%, 80%, and 90%. The model's efficacy was assessed using precision, recall, F1-score, accuracy, and support metrics, alongside receiver operating characteristic (ROC) and precision-recall (PR) curves. The ROC curves were quantified using the area under the curve (AUC) metric. Results indicated that the model's performance improved with an increased size of the training dataset. Specifically, the 80% training data model achieved the highest AUC, suggesting superior classification ability over the models trained with 70% and 90% data. PR analysis revealed a steep trade-off between precision and recall across all datasets, with 80% training data again demonstrating a slightly better balance. This is indicative of the challenges faced in achieving high precision with a concurrently high recall, a common issue in imbalanced datasets such as those found in medical diagnostics.

Cirrhosis, advanced liver disease, affects 2 to 5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion (hepatic encephalopathy), and ascites, reducing life expectancy from 12 to less than 2 years. Among patients with compensated cirrhosis, identifying patients at high risk of decompensation is critical to optimize care and reduce morbidity and mortality. Therefore, it is important to preferentially direct them towards specialty care which cannot be provided to all patients with cirrhosis. We used discovery top-down proteomics to identify differentially expressed proteoforms (DEPs) in the plasma of patients with progressive stages of liver cirrhosis with the ultimate goal to identify candidate biomarkers of disease progression. In this pilot study, we identified 209 DEPs across three stages of cirrhosis (compensated, compensated with portal hypertension, and decompensated), of which 115 derived from proteins enriched in the liver at a transcriptional level and discriminated the three stages of cirrhosis. Enrichment analyses demonstrated DEPs are involved in several metabolic and immunological processes known to be impacted by cirrhosis progression. We have preliminarily defined the plasma proteoform signatures of cirrhosis patients, setting the stage for ongoing discovery and validation of biomarkers for early diagnosis, risk stratification, and disease monitoring.

Cirrhosis represents a significant global health challenge, characterized by high morbidity and mortality rates that severely impact human health. Timely and precise prognostic assessments of liver cirrhosis are crucial for improving patient outcomes and reducing mortality rates as they enable physicians to identify high-risk patients and implement early interventions. This paper features a thorough literature review on the prognostic assessment of liver cirrhosis, aiming to summarize and delineate the present status and constraints associated with the application of traditional prognostic tools in clinical settings. Among these tools, the Child-Pugh and Model for End-Stage Liver Disease (MELD) scoring systems are predominantly utilized. However, their accuracy varies significantly. These systems are generally suitable for broad assessments but lack condition-specific applicability and fail to capture the risks associated with dynamic changes in patient conditions. Future research in this field is poised for deep exploration into the integration of artificial intelligence (AI) with routine clinical and multi-omics data in patients with cirrhosis. The goal is to transition from static, unimodal assessment models to dynamic, multimodal frameworks. Such advancements will not only improve the precision of prognostic tools but also facilitate personalized medicine approaches, potentially revolutionizing clinical outcomes.

Cirrhosis, advanced liver disease, affects 2-5 million Americans. While most patients have compensated cirrhosis and may be fairly asymptomatic, many decompensate and experience life-threatening complications such as gastrointestinal bleeding, confusion (hepatic encephalopathy), and ascites, reducing life expectancy from 12 to less than 2 years. Among patients with compensated cirrhosis, identifying patients at high risk of decompensation is critical to optimize care and reduce morbidity and mortality. Therefore, it is important to preferentially direct them towards specialty care which cannot be provided to all patients with cirrhosis. We used discovery Top-down Proteomics (TDP) to identify differentially expressed proteoforms (DEPs) in the plasma of patients with progressive stages of liver cirrhosis with the ultimate goal to identify candidate biomarkers of disease progression. In this pilot study, we identified 209 DEPs across three stages of cirrhosis (compensated, compensated with portal hypertension, and decompensated), of which 115 derived from proteins enriched in the liver at a transcriptional level and discriminated the three stages of cirrhosis. Enrichment analyses demonstrated DEPs are involved in several metabolic and immunological processes known to be impacted by cirrhosis progression. We have preliminarily defined the plasma proteoform signatures of cirrhosis patients, setting the stage for ongoing discovery and validation of biomarkers for early diagnosis, risk stratification, and disease monitoring.

Prediction of short-term mortality in patients with acute decompensation of liver cirrhosis could be improved. We aimed to develop and validate two machine learning (ML) models for predicting 28-day and 90-day mortality in patients hospitalized with acute decompensated liver cirrhosis. We trained two artificial neural network (ANN)-based ML models using a training sample of 165 out of 290 (56.9%) patients, and then tested their predictive performance against Model of End-stage Liver Disease-Sodium (MELD-Na) and MELD 3.0 scores using a different validation sample of 125 out of 290 (43.1%) patients. The area under the ROC curve (AUC) for predicting 28-day mortality for the ML model was 0.811 (95%CI: 0.714- 0.907; p < 0.001), while the AUC for the MELD-Na score was 0.577 (95%CI: 0.435-0.720; p = 0.226) and for MELD 3.0 was 0.600 (95%CI: 0.462-0.739; p = 0.117). The area under the ROC curve (AUC) for predicting 90-day mortality for the ML model was 0.839 (95%CI: 0.776- 0.884; p < 0.001), while the AUC for the MELD-Na score was 0.682 (95%CI: 0.575-0.790; p = 0.002) and for MELD 3.0 was 0.703 (95%CI: 0.590-0.816; p < 0.001). Our study demonstrates that ML-based models for predicting short-term mortality in patients with acute decompensation of liver cirrhosis perform significantly better than MELD-Na and MELD 3.0 scores in a validation cohort.

Chronic liver disease and cirrhosis are persistent global health threats, ranking among the top causes of death. Despite medical advancements, their mortality rates have remained stagnant for decades. Existing scoring systems such as Child-Turcotte-Pugh and Mayo End-Stage Liver Disease have limitations, prompting the exploration of more accurate predictive methods using artificial intelligence and machine learning (ML).

We retrospectively reviewed the data of all adult patients with acute decompensated liver cirrhosis admitted to a tertiary hospital during 2015-2021. The dataset underwent preprocessing to handle missing values and standardize continuous features. Traditional ML and deep learning algorithms were applied to build a 28-day mortality prediction model.

The subjects were 173 cirrhosis patients, whose medical records were examined. We developed and evaluated multiple models for 28-day mortality prediction. Among traditional ML algorithms, logistic regression outperformed was achieving an accuracy of 82.9%, precision of 55.6%, recall of 71.4%, and an F1-score of 0.625. Naive Bayes and Random Forest models also performed well, both achieving the same accuracy (82.9%) and precision (54.5%). The deep learning models (multilayer artificial neural network, recurrent neural network, and Long Short-Term Memory) exhibited mixed results, with the multilayer artificial neural network achieving an accuracy of 74.3% but lower precision and recall. The feature importance analysis identified key predictability contributors, including admission in the intensive care unit (importance: 0.112), use of mechanical ventilation (importance: 0.095), and mean arterial pressure (importance: 0.073).

Our study demonstrates the potential of ML in predicting 28-day mortality following hospitalization with acute decompensation of liver cirrhosis. Logistic Regression, Naive Bayes, and Random Forest models proved effective, while deep learning models exhibited variable performance. These models can serve as useful tools for risk stratification and timely intervention. Implementing these models in clinical practice has the potential to improve patient outcomes and resource allocation.

Liver transplantation (LT) is a life-saving treatment for individuals with end-stage liver disease. The management of LT recipients is complex, predominantly because of the need to consider demographic, clinical, laboratory, pathology, imaging, and omics data in the development of an appropriate treatment plan. Current methods to collate clinical information are susceptible to some degree of subjectivity; thus, clinical decision-making in LT could benefit from the data-driven approach offered by artificial intelligence (AI). Machine learning and deep learning could be applied in both the pre- and post-LT settings. Some examples of AI applications pre-transplant include optimising transplant candidacy decision-making and donor-recipient matching to reduce waitlist mortality and improve post-transplant outcomes. In the post-LT setting, AI could help guide the management of LT recipients, particularly by predicting patient and graft survival, along with identifying risk factors for disease recurrence and other associated complications. Although AI shows promise in medicine, there are limitations to its clinical deployment which include dataset imbalances for model training, data privacy issues, and a lack of available research practices to benchmark model performance in the real world. Overall, AI tools have the potential to enhance personalised clinical decision-making, especially in the context of liver transplant medicine.

The mortality scoring systems for patients with end-stage liver disease have evolved from the Child-Turcotte-Pugh score to the model for end-stage liver disease (MELD) score, affecting the wait list for liver allocation. There are inherent weaknesses in the MELD score, with the gradual decline in its accuracy owing to changes in patient demographics or treatment options. Continuous refinement of the MELD score is in progress; however, both advantages and disadvantages exist. Recently, attempts have been made to introduce artificial intelligence into mortality prediction; however, many challenges must still be overcome. More research is needed to improve the accuracy of mortality prediction in liver transplant recipients.

In this review article, we discuss the model for end-stage liver disease (MELD) score and its dual purpose in general and transplant hepatology. As the landscape of liver disease and transplantation has evolved considerably since the advent of the MELD score, we summarise emerging concepts, methodologies, and technologies that may improve mortality prognostication in the future. Finally, we explore how these novel concepts and technologies may be incorporated into clinical practice.

In recent years, there have been important advances in our understanding of alcohol-associated hepatitis (AH), which have occurred in parallel with a surge in clinical trial activity. Meanwhile, the broader medical field has seen a transformation in care paradigms based on emerging digital technologies. This review focuses on breakthroughs in our understanding of AH and how these breakthroughs are leading to new paradigms for biomarker discovery, clinical trial activity, and care models for patients. It portends a future in which multimodal data from genetic, radiomic, histologic, and environmental sources can be integrated and synthesised to generate personalised biomarkers and therapies for patients with AH.